DX-88 ecallantide: Phase III data

Top-line data from the double-blind, placebo-controlled, U.S. and Canadian Phase III EDEMA4 trial in 96 patients, showed that those receiving 30 mg of subcutaneous DX-88 met the primary endpoint of si...